Lundbeck at neutral by Merrill

Lundbeck was given a neutral rating by Merrill Lynch analyst Erica Whittaker on news that the company's Lexapro U.S. marketing partner Forrest announced that due to slowing growth in the antidepressant market, it would reduce its Lexapro inventory from 16 months to 10 months. With an estimated half of Lundbeck's Lexapro income from Forest derived from Lexapro bulk shipments, Merrill reduced its 2006 Lexapro revenue forecast by 34% from Danish kroner 2.6 billion to kroner $1.7 billion. Shares of the Copenhagen, Denmark, pharmaceutical company were down kroner 1.75, or 1.31%, at kroner $131.50 on volume of 3,199,638 shares versus the three-month running average of 972,529 shares. (Copenhagen: LUN.CO)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.